James Laird, MD
Assistant Professor of Therapeutic Radiology
Research & Publications
Biography
Coauthors
Selected Publications
- Radiation PneumonitisLaird J, Decker R, Roberts K, Park H. Radiation Pneumonitis. In: Grippi M, Antin-Ozerkis D, Dela Cruz C, Kotloff R, Kotton C, Pack A (editors). Fishman’s Pulmonary Diseases and Disorders, 6th edition. New York: McGraw-Hill: 2023; p. 966-986.
- Early Laryngeal CancerCrosby T, Laird J, Park H, McWharter A. Early Laryngeal Cancer. In: Johnson J and Rosen C (editors). Bailey’s Head & Neck Surgery Otolaryngology, 6th Edition. Philadelphia: LWW: 2022; Chapter 141.
- Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast CancerLaird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.
- Drivers of Medicare Spending: A 15-Year Review of Radiation Oncology Charges Allowed by the Medicare Physician/Supplier Fee-for-Service Program Compared With Other SpecialtiesMokhtech M, Laird JH, Maroongroge S, Zhu D, Falit B, Johnstone PAS, Mantz CA, Ennis RD, Sandler HM, Dosoretz AP, Yu JB. Drivers of Medicare Spending: A 15-Year Review of Radiation Oncology Charges Allowed by the Medicare Physician/Supplier Fee-for-Service Program Compared With Other Specialties. International Journal Of Radiation Oncology • Biology • Physics 2021, 110: 322-327. PMID: 33412264, DOI: 10.1016/j.ijrobp.2020.12.051.
- Ovarian CancerLaird J, Tymon-Rosario J, Damast S. Ovarian Cancer. 2020 DOI: 10.1891/9780826155146.0026.
- Endometrial CancerLaird J, An Y, Damast S. Endometrial Cancer. 2020 DOI: 10.1891/9780826155146.0027.
- Cervical CancerLaird J, Young M, Damast S. Cervical Cancer. 2020 DOI: 10.1891/9780826155146.0028.
- Vaginal CancerLaird J, Damast S. Vaginal Cancer. 2020 DOI: 10.1891/9780826155146.0029.
- Vulvar CancerLaird J, Young M, Damast S. Vulvar Cancer. 2020 DOI: 10.1891/9780826155146.0030.
- Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived XenograftsLaird J, Lok B, Carney B, Kossatz S, de Stanchina E, Reiner T, Poirier J, Rudin C. Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived Xenografts. Journal Of Thoracic Oncology 2019, 14: 1743-1752. PMID: 31195178, PMCID: PMC6764879, DOI: 10.1016/j.jtho.2019.05.032.
- Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignanciesMa J, Laird J, Chau K, Chelius M, Lok B, Yahalom J. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Medicine 2018, 8: 58-66. PMID: 30597769, PMCID: PMC6346231, DOI: 10.1002/cam4.1844.
- ASO Author Reflections: Breast Cancer Local Recurrence Versus New Primary-Clinical Predictors and Prognostic Implications.Laird J, Braunstein LZ. ASO Author Reflections: Breast Cancer Local Recurrence Versus New Primary-Clinical Predictors and Prognostic Implications. Ann Surg Oncol 2018, 25: 648-649. PMID: 30306376, DOI: 10.1245/s10434-018-6889-4.
- Reply to "Questions About In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy".Laird J, Braunstein LZ. Reply to "Questions About In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy". Ann Surg Oncol 2018, 25: 3779. PMID: 29270878, DOI: 10.1245/s10434-017-6286-4.
- Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and XenograftsLaird J, Lok B, Ma J, Bell A, de Stanchina E, Poirier J, Rudin C. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clinical Cancer Research 2018, 24: 5143-5152. PMID: 29945991, PMCID: PMC6742772, DOI: 10.1158/1078-0432.ccr-18-0401.
- Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of InvolvementLaird J, Ma J, Chau K, Chelius M, Shi W, Zhang Z, Lok B, Yahalom J. Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement. International Journal Of Radiation Oncology • Biology • Physics 2017, 100: 670-678. PMID: 29413280, PMCID: PMC5806138, DOI: 10.1016/j.ijrobp.2017.10.053.
- Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving TherapyLaird J, Lok B, Siu C, Cahlon O, Khan A, McCormick B, Powell S, Cody H, Wen H, Ho A, Braunstein L. Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy. Annals Of Surgical Oncology 2017, 25: 154-163. PMID: 29094250, PMCID: PMC5827945, DOI: 10.1245/s10434-017-6209-4.
- Unravelling the biology of SCLC: implications for therapySabari J, Lok B, Laird J, Poirier J, Rudin C. Unravelling the biology of SCLC: implications for therapy. Nature Reviews Clinical Oncology 2017, 14: 549-561. PMID: 28534531, PMCID: PMC5843484, DOI: 10.1038/nrclinonc.2017.71.